Pregnancy and Multiple Sclerosis (MS): A Beneficial Association. Possible therapeutic application of embryo-specific Pre-implantation Factor (PIF*)

American Journal of Reproductive Immunology

Volumn 68, Issue 6, 2012, Pages 456-464

  Paidas, Michael J ^a   Annunziato, Jack ^a   Romano, Michael ^a   Weiss, Lola ^b   Or, Reuven ^b   Barnea, Eytan R ^c,d,e  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c Society for the Investigation of Early Pregnancy (SIEP)   (United States)

^d BioIncept LLC   (United States)

^e RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Inflammation; Multiple sclerosis; Pregnancy; Preimplantation factor; Therapy

Indexed keywords

ALPHA FETOPROTEIN; AZATHIOPRINE; BETA1A INTERFERON; BETAMETHASONE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; DEXAMETHASONE; ESTRIOL; ESTROGEN; FINGOLIMOD; GLATIRAMER; IMMUNOMODULATING AGENT; METHOTREXATE; METHYLPREDNISOLONE; NATALIZUMAB; ORAL CONTRACEPTIVE AGENT; PEPTIDE; PRE IMPLANTATION FACTOR; PREDNISOLONE; PREDNISONE; UNCLASSIFIED DRUG; VITAMIN D;

ABORTION; ANENCEPHALUS; ANTIGEN PRESENTING CELL; CORTICOSTEROID THERAPY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG RECEPTOR BINDING; HUMAN; HYDROCEPHALUS; INHERITANCE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PARALYSIS; PREGNANCY; PRIORITY JOURNAL; REVIEW; SMOKING; T LYMPHOCYTE; VITAMIN D DEFICIENCY;

ALPHA-FETOPROTEINS; FEMALE; HUMANS; INFLAMMATION; MALE; MULTIPLE SCLEROSIS; NERVE REGENERATION; NEUROPROTECTIVE AGENTS; PARALYSIS; PEPTIDES; PREGNANCY; PREGNANCY COMPLICATIONS; TH1 CELLS; TH2 CELLS; VITAMIN D DEFICIENCY;

EID: 84869033109     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/j.1600-0897.2012.01170.x     Document Type: Review

References (75)

1. Bettelli E, Korn T, Oukka M, Kuchroo VK: Induction and effector functions of T(H)17 cells. Nature 2008; 453:1051-1057.
2. Basu A, Krady JK, Levison SW: Interleukin-1: a master regulator of neuroinflammation. J Neurosci Res 2004; 78:151-156.
3. Hafler DA: Multiple Sclerosis. J Clin Invest 2004; 113:788-794.
4. Nicolo C, Sali M, Di Sante G, Geloso MC, Signori E, Penitente R, Uniyal S, Rinaldi M, Ingrosso L, Fazio VM, Chan BM, Delogu G, Ria F: Mycobacterium smegmatis expressing a chimeric protein MPT64-proteolipid protein (PLP) 139-151 reorganizes the PLP-specific T cell repertoire favoring a CD8-mediated response and induces a relapsing experimental autoimmune encephalomyelitis. J Immunol 2010; 184:222-235.
5. Al-Shammri S, Rawoot P, Azizieh F, AbuQoora A, Hanna M, Saminathan TR, Raghupathy R: Th1/Th2 cytokine patterns and clinical profiles during and after pregnancy in women with multiple sclerosis. J Neurol Sci 2004; 222:21-27.
6. Langer-Gould A, Garren H, Slansky A, Ruiz PJ, Steinman L: Late pregnancy suppresses relapses in experimental autoimmune encephalomyelitis: evidence for a suppressive pregnancy-related serum factor. J Immunol 2002; 169:1084-1091.
7. Sadovnick AD, Yee IM, Ebers GC: Factors influencing sib risks for multiple sclerosis. Clin Genet 2000; 58:431-435.
8. Sadovnick AD, Dircks A, Ebers GC: Genetic counselling in multiple sclerosis: risks to sibs and children of affected individuals. Clin Genet 1999; 56:118-122.
9. Salzer J, Svenningsson A, Sundstrom P: Season of birth and multiple sclerosis in Sweden. Acta Neurol Scand 2010; 122:70-73.
10. Nashold FE, Hoag KA, Goverman J, Hayes CE: Rag-1-dependent cells are necessary for 1, 25-dihydroxyvitamin D(3) prevention of experimental autoimmune encephalomyelitis. J Neuroimmunol 2001; 119:16-29.
11. Hayes CE, Nashold FE, Spach KM, Pedersen LB: The immunological functions of the vitamin D endocrine system. Cell Mol Biol (Noisy-le-grand) 2003; 49:277-300.
12. Sospedra M, Martin R: Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23:683-747.
13. Gilli F, Lindberg RL, Valentino P, Marnetto F, Malucchi S, Sala A, Capobianco M, di Sapio A, Sperli F, Kappos L, Calogero RA, Bertolotto A: Learning from nature: pregnancy changes the expression of inflammation-related genes in patients with multiple sclerosis. PLoS ONE 2010; 5:e8962.
14. DeLuca J, Nocentini U: Neuropsychological, medical and rehabilitative management of persons with multiple sclerosis. NeuroRehabilitation 2011; 29:197-219.
15. Mirzaei F, Michels KB, Munger K, O'Reilly E, Chitnis T, Forman MR, Giovannucci E, Rosner B, Ascherio A: Gestational vitamin D and the risk of multiple sclerosis in offspring. Ann Neurol 2011; 70:30-40.
16. Watson PE, McDonald BW: Seasonal variation of nutrient intake in pregnancy: effects on infant measures and possible influence on diseases related to season of birth. Eur J Clin Nutr 2007; 61:1271-1280.
17. Fu Y, Talavage TM, Cheng JX: New imaging techniques in the diagnosis of multiple sclerosis. Expert Opin Med Diagn 2008; 2:1055-1065.
18. Kiferle L, Politis M, Muraro PA, Piccini P: Positron emission tomography imaging in multiple sclerosis-current status and future applications. Eur J Neurol 2011; 18:226-231.
19. Orton SM, Herrera BM, Yee IM, Valdar W, Ramagopalan SV, Sadovnick AD, Ebers GC: Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 2006; 5:932-936.
20. D'Hooghe MB, Haentjens P, Nagels G, D'Hooghe T, De Keyser J: Menarche, oral contraceptives, pregnancy and progression of disability in relapsing onset and progressive onset multiple sclerosis. J Neurol 2012; 259:855-861.
21. Tsui A, Lee MA: Multiple sclerosis and pregnancy. Curr Opin Obstet Gynecol 2011; 23:435-439.
22. Jalkanen A, Alanen A, Airas L: Pregnancy outcome in women with multiple sclerosis: results from a prospective nationwide study in Finland. Mult Scler 2010; 16:950-955.
23. Bader AM, Hunt CO, Datta S, Naulty JS, Ostheimer GW: Anesthesia for the obstetric patient with multiple sclerosis. J Clin Anesth 1988; 1:21-24.
24. Runmarker B, Andersen O: Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain 1995;118(Pt 1):253-261.
25. Vukusic S, Hutchinson M, Hours M, Moreau T, Cortinovis-Tourniaire P, Adeleine P, Confavreux C: The Pregnancy In Multiple Sclerosis G: Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 2004; 127:1353-1360.
26. Vukusic S, Confavreux C: Pregnancy and multiple sclerosis: the children of PRIMS. Clin Neurol Neurosurg 2006; 108:266-270.
27. Orvieto R, Achiron R, Rotstein Z, Noy S, Bar-Hava I, Achiron A: Pregnancy and multiple sclerosis: a 2-year experience. Eur J Obstet Gynecol Reprod Biol 1999; 82:191-194.
28. Salemi G, Callari G, Gammino M, Battaglieri F, Cammarata E, Cuccia G, D'Amelio M, Lupo I, Ragonese P, Savettieri G: The relapse rate of multiple sclerosis changes during pregnancy: a cohort study. Acta Neurol Scand 2004; 110:23-26.
29. Langer-Gould A, Huang SM, Gupta R, Leimpeter AD, Greenwood E, Albers KB, Van Den Eeden SK, Nelson LM: Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch Neurol 2009; 66:958-963.
30. Lykke JA, Langhoff-Roos J, Lockwood CJ, Triche EW, Paidas MJ: Mortality of mothers from cardiovascular and non-cardiovascular causes following pregnancy complications in first delivery. Paediatr Perinat Epidemiol 2010; 24:323-330.
31. Coyle PK, Christie S, Fodor P, Fuchs K, Giesser B, Gutierrez A, Lynn J, Weinstock-Guttman B, Pardo L: Multiple sclerosis gender issues: clinical practices of women neurologists. Mult Scler 2004; 10:582-588.
32. Ferrero S, Pretta S, Ragni N: Multiple sclerosis: management issues during pregnancy. Eur J Obstet Gynecol Reprod Biol 2004; 115:3-9.
33. Janssen NM, Genta MS: The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med 2000; 160:610-619.
34. Salminen HJ, Leggett H, Boggild M: Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes. J Neurol 2010; 257:2020-2023.
35. Weber-Schoendorfer C, Schaefer C: Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult Scler 2009; 15:1037-1042.
36. Sandberg-Wollheim M, Alteri E, Moraga MS, Kornmann G: Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Mult Scler 2011; 17:423-430.
37. Piehl F, Holmen C, Hillert J, Olsson T: Swedish natalizumab (Tysabri) multiple sclerosis surveillance study. Neurol Sci 2011; 31(Suppl 3):289-293.
38. Wehner NG, Shopp G, Rocca MS, Clarke J: Effects of natalizumab, an alpha4 integrin inhibitor, on the development of Hartley guinea pigs. Birth Defects Res B Dev Reprod Toxicol 2009; 86:98-107.
39. Wehner NG, Skov M, Shopp G, Rocca MS, Clarke J: Effects of natalizumab, an alpha4 integrin inhibitor, on fertility in male and female guinea pigs. Birth Defects Res B Dev Reprod Toxicol 2009; 86:108-116.
40. Wehner NG, Shopp G, Osterburg I, Fuchs A, Buse E, Clarke J: Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an alpha4 integrin inhibitor. Birth Defects Res B Dev Reprod Toxicol 2009; 86:144-156.
41. Hellwig K, Haghikia A, Gold R: Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler 2011; 17:958-963.
42. Scott LJ: Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis. CNS Drugs 2011; 25:673-698.
43. Lu E, Dahlgren L, Sadovnick A, Sayao A, Synnes A, Tremlett H: Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs. Mult Scler 2012; 18:460-467.
44. Johnston A, Gudjonsson JE, Sigmundsdottir H, Ludviksson BR, Valdimarsson H: The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 2005; 114:154-163.
45. Mazerski J, Martelli S, Borowski E: The geometry of intercalation complex of antitumor mitoxantrone and ametantrone with DNA: molecular dynamics simulations. Acta Biochim Pol 1998; 45:1-11.
46. Craig A, Ling Luo N, Beardsley DJ, Wingate-Pearse N, Walker DW, Hohimer AR, Back SA: Quantitative analysis of perinatal rodent oligodendrocyte lineage progression and its correlation with human. Exp Neurol 2003; 181:231-240.
47. Nalbandian G, Kovats S: Understanding sex biases in immunity: effects of estrogen on the differentiation and function of antigen-presenting cells. Immunol Res 2005; 31:91-106.
48. Salem ML, Matsuzaki G, Kishihara K, Madkour GA, Nomoto K: beta-estradiol suppresses T cell-mediated delayed-type hypersensitivity through suppression of antigen-presenting cell function and Th1 induction. Int Arch Allergy Immunol 2000; 121:161-169.
49. Saito S, Foegh ML, Motomura N, Lou H, Kent K, Ramwell PW: Estradiol inhibits allograft-inducible major histocompatibility complex class II antigen expression and transplant arteriosclerosis in the absence of immunosuppression. Transplantation 1998; 66:1424-1431.
50. Wira CR, Roche MA, Rossoll RM: Antigen presentation by vaginal cells: role of TGFbeta as a mediator of estradiol inhibition of antigen presentation. Endocrinology 2002; 143:2872-2879.
51. Hoek A, Allaerts W, Leenen PJ, Schoemaker J, Drexhage HA: Dendritic cells and macrophages in the pituitary and the gonads. Evidence for their role in the fine regulation of the reproductive endocrine response. Eur J Endocrinol 1997; 136:8-24.
52. Polanczyk MJ, Carson BD, Subramanian S, Afentoulis M, Vandenbark AA, Ziegler SF, Offner H: Cutting edge: estrogen drives expansion of the CD4 + CD25 + regulatory T cell compartment. J Immunol 2004; 173:2227-2230.
53. Hernan MA, Hohol MJ, Olek MJ, Spiegelman D, Ascherio A: Oral contraceptives and the incidence of multiple sclerosis. Neurology 2000; 55:848-854.
54. Alonso A, Jick SS, Olek MJ, Ascherio A, Jick H, Hernan MA: Recent use of oral contraceptives and the risk of multiple sclerosis. Arch Neurol 2005; 62:1362-1365.
55. Alonso A, Clark CJ: Oral contraceptives and the risk of multiple sclerosis: a review of the epidemiologic evidence. J Neurol Sci 2009; 286:73-75.
56. Papenfuss TL, Powell ND, McClain MA, Bedarf A, Singh A, Gienapp IE, Shawler T, Whitacre CC: Estriol generates tolerogenic dendritic cells in vivo that protect against autoimmunity. J Immunol 2011; 186:3346-3355.
57. Irony-Tur-Sinai M, Grigoriadis N, Lourbopoulos A, Pinto-Maaravi F, Abramsky O, Brenner T: Amelioration of autoimmune neuroinflammation by recombinant human alpha-fetoprotein. Exp Neurol 2006; 198:136-144.
58. Barnea ER: The embryo: a privileged entity in a privileged site: lessons learnt from embryonal development. Early Pregnancy 1997; 3:77-80.
59. Barnea ER, Simon J, Levine SP, Coulam CB, Taliadouros GS, Leavis PC: Progress in characterization of pre-implantation factor in embryo cultures, in vivo. Immunol Am Reprod J 1999; 42:95-99.
60. Barnea ER: Current progress in early pregnancy investigation, the steps ahead. Early Pregnancy 2000; 4:1-4.
61. Barnea ER: Embryo maternal dialogue: from pregnancy recognition to proliferation control. Early Pregnancy 2001; 5:65-66.
62. Barnea ER: Insight into early pregnancy events: the emerging role of the embryo. Immunol Am Reprod J 2004; 51:319-322.
63. Barnea ER: Signaling between embryo and mother in early pregnancy: basis for development of tolerance. In Recurrent Pregnancy Loss, HJA Carp (ed). London, Taylor & Francis, 2007, pp 15-21.
64. Than NG, Paidas MJ, Mizutani S, Sharma S, Padbury J, Barnea ER: Embryo-placento-maternal interaction and biomarkers: from diagnosis to therapy-a workshop report. Placenta 2007; 28(Suppl A):S107-S110.
65. Stamatkin CW, Roussev RG, Stout M, Absalon-Medina V, Ramu S, Goodman C, Coulam CB, Gilbert RO, Godke RA, Barnea ER: Preimplantation Factor (PIF) correlates with early mammalian embryo development - bovine and murine models. Reprod Biol Endocrinol 2011; 9:63.
66. Stamatkin CW, Roussev RG, Stout M, Coulam CB, Triche E, Godke RA, Barnea ER: Preimplantation factor negates embryo toxicity and promotes embryo development in culture. Reprod Biomed Online 2011; 23:517-524.
67. Paidas MJ, Krikun G, Huang SJ, Jones R, Romano M, Annunziato J, Barnea ER: A genomic and proteomic investigation of the impact of preimplantation factor on human decidual cells. Am J Obstet Gynecol 2010; 202:459 e451-e458.
68. Paidas MJ, Kirk D, Barnea ER: Is Embryo-Derived PreImplantation Factor (PIF*) Critical for Implantation? Promotes Endometrial Receptivity Enhancing Integrin-α2β3, Modulating Decidual Growth-Factors and Associated MAPK Pathways. In press RB&E 2012.
69. Duzyj CM, Barnea ER, Li M, Huang SJ, Krikun G, Paidas MJ: Preimplantation factor promotes first trimester trophoblast invasion. Am J Obstet Gynecol 2010; 203:402 e401-404.
70. Barnea ER: Applying embryo-derived immune tolerance to the treatment of immune disorders. Ann N Y Acad Sci 2007; 1110:602-618.
71. Barnea ER, Kirk D, Ramu S, Rivnay B, Sathiyaseelan T, Stamatkin C, Roussev R, Paidas MJ: Preimplantation Factor (PIF*) Orchestrates Systemic Anti-inflammatory Response by Immune Cells: a Direct Effect on Peripheral Blood Mononuclear Cells (PBMC). Am J Obstet Gynecol 2012; 206:S36-S37.
72. Roussev R, Dons'koi B, Stamatkin C, Ramu S, Chernyshov V, Coulam CB, Barnea E: PreImplantation Factor (PIF*) inhibits circulating NK functional activity and NK activity by reducing CD69 expression: implications for Recurrent Pregnancy Loss (RPL) Therapy. Am J Reprod Immunol 2012; 67(Suppl. 1):43.
73. Weiss L, Bernstein S, Jones R, Amunugama R, Krizman D, Jebailey L, Almogi-Hazan O, Yekhtin Z, Shiner R, Reibstein I, Triche E, Slavin S, Or R, Barnea ER: Preimplantation factor (PIF) analog prevents type I diabetes mellitus (TIDM) development by preserving pancreatic function in NOD mice. Endocrine 2011; 40:41-54.
74. Weiss L, Or R, Jones RC, Amunugama R, JeBailey L, Ramu S, Bernstein SA, Yekhtin Z, Almogi-Hazan O, Shainer R, Reibstein I, Vortmeyer AO, Paidas MJ, Zeira M, Slavin S, Barnea ER: Preimplantation Factor (PIF*) reverses neuroinflammation while promoting neural repair in EAE model. J Neurol Sci 2011; 312:146-157.
75. Weiss L, Almogi-Hazan O, Shainer R, Triche E, Yekhtin Z, Vortmeyer AO, Paidas MJ, Or R, Barnea ER: Preimplantation Factor (PIF) is Superior to Glatiramer Acetate (GA) in Reversing Neuroinflammation/Multiple Sclerosis: Experimental Autoimmune Encephalomyelitis (EAE) Murine Model Study. 8th International Congress on Autoimmunity, Granada, Spain 2012, May 9.